Nvni Group (NASDAQ:NVNI) versus Coeptis Therapeutics (NASDAQ:ZSQR) Head-To-Head Analysis

Coeptis Therapeutics (NASDAQ:ZSQR) and Nvni Group (NASDAQ:NVNI) are both small-cap technology companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, dividends, risk and institutional ownership.

Insider and Institutional Ownership

13.9% of Coeptis Therapeutics shares are held by institutional investors. Comparatively, 0.5% of Nvni Group shares are held by institutional investors. 24.2% of Coeptis Therapeutics shares are held by company insiders. Comparatively, 20.0% of Nvni Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

Coeptis Therapeutics has a beta of -0.19, meaning that its share price is 119% less volatile than the S&P 500. Comparatively, Nvni Group has a beta of -0.07, meaning that its share price is 107% less volatile than the S&P 500.

Profitability

This table compares Coeptis Therapeutics and Nvni Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	-773.72%	-49.45%	-46.88%
Nvni Group	N/A	N/A	N/A

Earnings and Valuation

This table compares Coeptis Therapeutics and Nvni Group”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coeptis Therapeutics	$1.36 million	145.59	-$11.92 million	($1.63)	-2.36
Nvni Group	$35.23 million	0.29	-$20.22 million	$0.40	2.57

Coeptis Therapeutics has higher earnings, but lower revenue than Nvni Group. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Nvni Group, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings for Coeptis Therapeutics and Nvni Group, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	1	0	0	0	1.00
Nvni Group	1	0	0	0	1.00

Summary

Nvni Group beats Coeptis Therapeutics on 7 of the 11 factors compared between the two stocks.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

About Nvni Group

Nvni Group Limited provides a business to business SaaS platform that offers cloud solutions. The company was incorporated in 2019 and is based in São Paulo, Brazil.